[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1989002277A3 - Prophylaxis and therapy of acquired immunodeficiency syndrome - Google Patents

Prophylaxis and therapy of acquired immunodeficiency syndrome Download PDF

Info

Publication number
WO1989002277A3
WO1989002277A3 PCT/US1988/002970 US8802970W WO8902277A3 WO 1989002277 A3 WO1989002277 A3 WO 1989002277A3 US 8802970 W US8802970 W US 8802970W WO 8902277 A3 WO8902277 A3 WO 8902277A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunodeficiency virus
human immunodeficiency
synthetic peptide
cell
amino acid
Prior art date
Application number
PCT/US1988/002970
Other languages
French (fr)
Other versions
WO1989002277A2 (en
Inventor
Ralph B Arlinghaus
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of WO1989002277A2 publication Critical patent/WO1989002277A2/en
Publication of WO1989002277A3 publication Critical patent/WO1989002277A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention involves a process for inducing resistance of an individual to infection by human immunodeficiency virus. The process involves vaccinating said individual with a synthetic peptide of mixture of peptides. The synthetic peptide(s) comprises an amino acid sequence derived at least in part from human immunodeficiency virus envelope protein conserved region. Upon antigenic presentation to an animal, this peptide induces directed cell-mediated immunity (i.e., T-cell cytotoxicity) to a substantially greater extent than production of antibody directed against native human immunodeficiency virus is elicited. The vaccine of the present invention comprises a synthetic peptide having an amino acid sequence derived at least in part from T-cell epitopes of human immunodeficiency virus envelope protein conserved region and preferably consists exclusively of T-cell epitopes.
PCT/US1988/002970 1987-08-28 1988-08-26 Prophylaxis and therapy of acquired immunodeficiency syndrome WO1989002277A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9064687A 1987-08-28 1987-08-28
US090,646 1987-08-28

Publications (2)

Publication Number Publication Date
WO1989002277A2 WO1989002277A2 (en) 1989-03-23
WO1989002277A3 true WO1989002277A3 (en) 1989-05-18

Family

ID=22223672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/002970 WO1989002277A2 (en) 1987-08-28 1988-08-26 Prophylaxis and therapy of acquired immunodeficiency syndrome

Country Status (2)

Country Link
AU (1) AU2914889A (en)
WO (1) WO1989002277A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
DE3937412A1 (en) * 1989-11-10 1991-05-16 Hoechst Ag SYNTHETIC VACCINE FOR THE SPECIFIC INDUCTION OF CYTOTOXIC T-LYMPHOZYTES
US6074650A (en) * 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5939074A (en) * 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
ATE134195T1 (en) * 1988-06-10 1996-02-15 United Biomedical Inc PEPTIDE FRAGMENTS OF HIV
FR2650954B1 (en) * 1989-08-18 1992-02-28 Pasteur Institut COMPOSITION RESULTING FROM THE BINDING OF AN EPITOPE B OF THE ENVELOPE GLYCOPROTEIN OF A TYPE IV RETROVIRUS AND A T-EPITOPE HAVING A DISTINCT PROTEIN ENCODED BY THIS RETROVIRUS AND THEIR APPLICATION TO THE PRODUCTION OF PROTECTIVE ANTIBODIES AGAINST AIDS
CA2025634A1 (en) * 1989-09-19 1991-03-20 Thomas Fuerst Peptides including ctl epitopes of hiv proteins and use thereof
US6248574B1 (en) * 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
CA2072351A1 (en) * 1990-01-05 1991-07-06 Andrew J. Mcmichael Hiv-1 core protein fragments
WO1991015512A2 (en) * 1990-04-03 1991-10-17 Genentech, Inc. Hiv envelope polypeptides
CA2114849C (en) * 1991-08-29 2007-04-24 Jay A. Berzofsky Multideterminant peptide antigens that stimulate helper t lymphocyte response to hiv in a range of human subjects
PT671947E (en) * 1991-12-02 2000-07-31 Univ Texas COMPOSITIONS FOR PRODUCING RESPONSES OF CITOTOXIC T-LYMPHOCYTES AGAINST VIRUSES
JPH09510437A (en) * 1993-12-28 1997-10-21 カイロン ミモトープス プロプライエトリー リミテッド T cell epitope
US5750332A (en) * 1994-01-19 1998-05-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptomers with enhanced immunogenicity
DE4405810A1 (en) 1994-02-23 1995-08-24 Behringwerke Ag Peptides derived from a retrovirus from the HIV group and their use
EP1980617A1 (en) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
JP2003523721A (en) 1998-12-31 2003-08-12 カイロン コーポレイション Polynucleotides encoding antigenic HIVC-type polypeptides, polypeptides, and uses thereof
PT1141315E (en) 1998-12-31 2008-05-05 Novartis Vaccines & Diagnostic Modified hiv env polypeptides
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP2412242A3 (en) 2001-07-05 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2003020876A2 (en) 2001-08-31 2003-03-13 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US6455670B1 (en) * 2001-09-06 2002-09-24 Tripep Ab Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203676A2 (en) * 1985-04-19 1986-12-03 The Wistar Institute Of Anatomy And Biology Vaccine for generating an immunogenic T cell response protective against a virus
EP0260714A2 (en) * 1986-09-19 1988-03-23 Oncogen Limited Partnership The use of activated t-lymphocytes for preparing a pharmaceutical composition for the treatment of AIDS
EP0273716A2 (en) * 1986-12-30 1988-07-06 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins
WO1988005440A1 (en) * 1987-01-16 1988-07-28 Institut Pasteur Peptides having immunological properties 2-hiv-2
EP0279994A2 (en) * 1986-12-31 1988-08-31 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Method to predict antigenic sites recognized by T-lymphocytes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203676A2 (en) * 1985-04-19 1986-12-03 The Wistar Institute Of Anatomy And Biology Vaccine for generating an immunogenic T cell response protective against a virus
EP0260714A2 (en) * 1986-09-19 1988-03-23 Oncogen Limited Partnership The use of activated t-lymphocytes for preparing a pharmaceutical composition for the treatment of AIDS
EP0273716A2 (en) * 1986-12-30 1988-07-06 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins
EP0279994A2 (en) * 1986-12-31 1988-08-31 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Method to predict antigenic sites recognized by T-lymphocytes
WO1988005440A1 (en) * 1987-01-16 1988-07-28 Institut Pasteur Peptides having immunological properties 2-hiv-2

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CELL, Vol. 45, June 1986, B.R. STARCICH et al.: "Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS", see page 637 - page 648, see the whole document. *
FEBS LETTERS, Vol. 218, No. 2, June 1987, M.J.E. STERNBERG et al.: "Prediction of antigenic determinants and secondary structures of the major AIDS virus proteins", see page 231 - page 237, see in particular fig. 3 page 236, "CONCLUSION". *
JOURNAL OF VIROLOGY, Vol. 61, No. 2, February 1987, SUSANNE MODROW et al.: "Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions", see page 570 - page 578, see the whole document. *
NATURE, Vol. 326, April 1987, A.R.M. COATES et al.: ""AIDS Vaccine Predictions"", see page 549 - page 550, see the whole document. *
PROC. NATL. ACAD. SCI. USA, Vol. 84, June 1987, KEMP B. CEASE et al.: "Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide", page 4249-4253, see fig. 1, last 4 lines (envT2) and page 4252, right col. 3rd paragraph. *

Also Published As

Publication number Publication date
AU2914889A (en) 1989-04-17
WO1989002277A2 (en) 1989-03-23

Similar Documents

Publication Publication Date Title
WO1989002277A3 (en) Prophylaxis and therapy of acquired immunodeficiency syndrome
US4474757A (en) Synthetic vaccine and process for producing same
IL91007A0 (en) Synthetic vaccine against aids virus
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
PT81338A (en) Antigens particularly envelope antigens of the virus of lymphadenopathies and of the acquired immuno-depressive syndrome and virus process for producing virus envelope antigens in the preparation of immunogenic compositions or for the diagnosis of the presence of antibodies against this virus
EP1001032A3 (en) Recombinant retroviruses delivering vector constructs to target cells
EP0328403A3 (en) Synthetic peptides related to the hiv-gp120-env-protein, and their use
EP0109942A3 (en) Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine
GB2220939B (en) Peptide fragments of hiv and their use in vaccines and diagnosis
HK141494A (en) Peptide fragments of HIV
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
Audibert et al. Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens
LOLEIT et al. Conjugates of synthetic lymphocyte-activating lipopeptides with segments from HIV proteins induce protein-specific antibody formation
EP0327180A3 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
GR3003754T3 (en)
NZ224251A (en) Synthetic rhinovirus (hrv) peptides and vaccines
DE69433057D1 (en) PEPTIDES FOR USE IN VACCINATING AND INDUCING NEUTRALIZING ANTIBODIES AGAINST THE HUMAN IMMUNE VIRUS
GB9021942D0 (en) Hiv related peptides
EP0320034A3 (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine
Mannhalter et al. Immunization of Chimpanzees with Recombinant gp160, but not Infection with Human Immunodeficiency Virus Type 1, Induces Envelope-Specific Thl Memory Cells
Dietzschold et al. Synthesis of an antigenic determinant of the HSV gD that stimulates the induction of virus-neutralizing antibodies and confers protection against a lethal challenge of HSV.
Ivanoff et al. Human immunodeficiency virus antigen.
PT91600A (en) Process for the preparation of a vaccine against flu virus containing a vaccinal polypeptide and such polypeptide
JPH05271282A (en) Synthetic peptide containing cyclic hiv principal neutralizing determinant and t-cell stimulatory epitope

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642